Abstracts Archive - Page 242 of 1683 - ATC Abstracts

2021 American Transplant Congress
Infectious Complications After Belatacept Conversion in Kidney Transplant
J. E. Marvin¹, D. Amenyedor¹, M. M. Azar², K. Belfield¹, V. Do¹, R. Formica³, E. Cohen¹
¹Pharmacy, Yale New Haven Hospital, New Haven, CT, ²Section of Infectious Diseases, Yale School of Medicine, New Haven, CT, ³Section of Nephrology, Yale School of Medicine, New Haven, CT
*Purpose: Tacrolimus (tac), a calcineurin inhibitor, is associated with multiple adverse effects when used for immunosuppression following kidney transplant (KT). Belatacept (bela) is a monoclonal…
2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
N. Singh¹, T. Le¹, M. S. Naseer¹, S. Asmil¹, A. Palermini¹, A. Qamar¹, R. Chand¹, S. Tandukar¹, D. Aultman², H. Shokouh-Amiri², G. Zibari²
¹Transplant, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA, ²Advanced Surgery, John C. McDonald Regional Transplant Center - Willis Knighton Medical Center, Shreveport, LA
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…
2021 American Transplant Congress
Influence of Induction Therapy and Antiretroviral Regimen on Outcomes in HIV Positive Renal Transplant Recipients
C. Rogers Marks¹, C. Durand², J. Hand³, M. Abidi⁴, M. Malinis⁵, B. Barnaba², H. Patel⁶, C. D. Alonso⁶
¹Massachussetts General Hospital, Boston, MA, ²Johns Hopkins Medical Center, Baltimore, MD, ³Ochsner Medical Center, New Orleans, LA, ⁴Univ. of Colorado, Aurora, CO, ⁵Yale, New Haven, CT, ⁶Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: Transplantation of HIV+ individuals has become more common over the past decade with increasing data supporting good outcomes. Questions remain regarding the impact of…
2021 American Transplant Congress
Belatacept Pharmacokinetic Analysis Comparing Belatacept Early Steroid Withdrawal Trial (BEST) with Benefit and Benefit-ext Trials
A. Bickenbach¹, M. McGowan¹, B. Miyagawa², T. Mizuno², A. Shields³, A. Christianson¹, P. West-Thielke⁴, J. Leone⁵, E. Woodle¹, D. Kaufman⁶, A. Wiseman⁷, A. Matas⁸, A. Vinks²
¹U Cincinnati, Cincinnati, OH, ²Cincinnati Childrens Med Center, Cincinnati, OH, ³Christ Hospital, Cincinnati, OH, ⁴UIC, Chicago, IL, ⁵Tampa Gen, Tampa, FL, ⁶U Wisconsin, Madison, WI, ⁷Centura Transplant, Denver, CO, ⁸U Minnesota, Minneapolis, MN
*Purpose: Belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies where fixed mg/kg dosing compared a less intense(LI) and more intense(MI) regimen. LI was preferred…
2021 American Transplant Congress
Impact of High-Risk EBV Discordance Status on Survival Outcomes in Kidney Transplant Recipients: A Multivariable Analysis
A. Dinesh¹, S. Jackson², T. L. Pruett¹, S. Riad³
¹Division of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, MN, ²Biostatistics, Analytics Consulting Services- Solid Organ Transplant, M Health Fairview, Minneapolis, MN, ³Department of Medicine, University of Minnesota, Minneapolis, MN
*Purpose: High-risk EBV discordance has been linked to Post-Transplant Lymphoproliferative Disorder (PTLD) after kidney transplantation; however, the impact on recipient and graft survival is under-reported.…
2021 American Transplant Congress
The Metagenomic Landscape of Renal Transplant
A. Johnson¹, G. Karadkhele², C. Larsen²
¹Emory University, Atlanta, GA, ²Surgery, Emory University, Atlanta, GA
*Purpose: The selective targeting of T cells in transplant immunosuppression medications leads to a high rate of viral infections. Different immunosuppression regimens have been shown…
2021 American Transplant Congress
Among Patients with Pre-Transplant Donor-Specific Antibodies, the Disappearance of the Donor-Specific Antibodies at 3 Months is Not Associated with Less Rejection
S. Parajuli, A. Djamali, A. Kharel, B. Alzoubi, N. Bath, N. Garg, F. Aziz, D. Mandelbrot
University of Wisconsin, Madison, WI
*Purpose: The number of sensitized kidney transplant recipients (KTRs) are increasing on the waiting list. Some KTRs receive an organ in the presence of pretransplant…
2021 American Transplant Congress
The Effect of Daratumumab (Dara, Humanized Anti-CD38 Monoclonal Antibody) on Immune Cells In Vitro and in a HLA-Sensitized Kidney Transplant Patient (HS KTx Pt) Desensitized (DES) with Dara
S. Ge¹, M. Chu¹, A. De Guzman¹, E. Ortiz¹, A. Vo², N. Ammerman², S. C. Jordan², M. Toyoda¹
¹Transplant Immunology Laboratory, Cedars Sinai Medical Center, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Antibody-Mediated Rejection (ABMR), primarily mediated by B cells, plasma cells (PC) and antibodies (Ab), is an obstacle for successful transplantation in HS KTx Pts.…
2021 American Transplant Congress
Home-based Liver Frailty Intervention (lift) in Liver Transplant Candidates: A Pilot Study
A. J. Thuluvath¹, K. Belfanti¹, S. Morrissey¹, O. Siddiqui¹, J. Peipert¹, A. Daud¹, J. Levitsky¹, T. Bogg², A. Flores¹, D. P. Ladner¹
¹Northwestern University Transplant Research Collaborative, Chicago, IL, ²Department of Psychology, Wayne State University, Detroit, MI
*Purpose: Frailty is highly prevalent in patients awaiting LT and is associated with increased waitlist and post-transplant mortality, hospitalizations and LOS. While reduction of frailty…
2021 American Transplant Congress
Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Sethi¹, S. Williamson¹, C. Myers¹, K. Lim¹, M. Gillespie¹, S. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a critical cytokine for plasma cell IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6. Here…